Physician profile
Peter Jonathan Riley
NPI 1154709566
$9,410.06
in general payments reported to CMS, 2019-2025
37 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $45.39 · 2021: $79.46 · 2022: $1,406 · 2023: $1,641 · 2024: $4,617 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,313 · Travel and Lodging: $2,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,313.36 |
| Travel and Lodging | $2,275.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,972.02 | 2022-2024 | Optis, Cardiomems, Diamondback Coronary |
| Shockwave Medical, INC | $1,068.33 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Novartis Pharmaceuticals Corporation | $722.76 | 2019-2025 | |
| Boston Scientific Corporation | $559.15 | 2019-2025 | Avvigo Guidance System, Watchman Flx |
| Medtronic, INC. | $286.98 | 2023-2024 | Corevalve Evolut R, Symplicity G3, Endurant Iis |
| Teleflex LLC | $263.59 | 2023-2025 | Turnpike, Guideliner, Vascband |
| W. L. Gore & Associates, INC. | $195.77 | 2021-2023 | Gore Cardioform Septal Occluder |
| Biotronik INC. | $194.64 | 2022 | |
| Abiomed | $186.47 | 2019-2025 | Impella |
| Kestra Medical Technology Services, INC. | $174.11 | 2022-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $168.74 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.28 | 2022-2025 | |
| Amgen INC. | $146.78 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $128.82 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Philips North America LLC | $128.51 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asahi Intecc USA, INC. | $125.00 | 2022 | |
| Impulse Dynamics (USA) INC. | $85.24 | 2023 | Optimizer |
| Bridgebio Pharma, INC. | $84.33 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $80.71 | 2019-2025 | |
| Pfizer INC. | $75.15 | 2024-2025 | |
| Cardiovascular Systems INC. | $69.64 | 2022 | |
| Cordis US Corp. | $62.75 | 2023 | Mynxgrip |
| Penumbra, INC. | $45.20 | 2025 | Ruby Coil, Indigo System |
| E.R. Squibb & Sons, L.L.C. | $44.79 | 2019-2025 | Eliquis |
| Atricure, INC. | $44.77 | 2023 | |
| Janssen Pharmaceuticals, INC | $40.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.13 | 2025 | |
| Alnylam Pharmaceuticals INC. | $37.78 | 2024-2025 | Onpattro |
| Biosense Webster, INC. | $37.04 | 2025 | Nuvision Ice Catheter |
| Regeneron Healthcare Solutions, INC. | $32.57 | 2024 | Evkeeza |
| Merck Sharp & Dohme LLC | $32.13 | 2022-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $23.96 | 2024 | Opsumit |
| Lilly USA, LLC | $21.59 | 2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $21.35 | 2025 | |
| Getinge USA Sales, LLC | $21.30 | 2021 | |
| Cardiva Medical, INC. | $20.90 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Celonova Biosciences, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.